Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07098858 · ClinicalTrials.gov registry record
The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry)
A clinical trial of Heart Failure, sponsored by EBR Systems.
- Recruiting
- Registry status
- 320
- Enrollment target
- 5
- Study locations
NCT07098858: Recruiting study of Heart Failure, sponsored by EBR Systems.
NCT07098858 is a study of Heart Failure that is actively recruiting participants, run by EBR Systems. The registered enrollment target is 320 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07098858, a study of Heart Failure, is actively recruiting participants, sponsored by EBR Systems.
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 5
- Study locations
Study Summary
Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System
Primary Outcome
The primary outcome measure of the Registry is the rate of serious adverse events (SAEs) at \< 30 days post implant related to the WiSE System and/or implant procedure.
Conditions Studied
Interventions
- DEVICE The Wise System
Study Locations (5)
Arkansas
- Arrhythmia Research Group (St. Bernards Hospital) - Jonesboro
Florida
- Naples Community Hospital - Naples
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medicine - New York
Pennsylvania
- Penn State Health - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2032-09-30 |
What NCT07098858 shows while recruiting
NCT07098858 is an observational study that tracks outcomes without assigning an intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which The Wise System is the first listed.
NCT07098858 lists 5 locations in 5 states (Arkansas, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT07098858 about?
NCT07098858 is a clinical study titled "The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry)". Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System
What is the current status of trial NCT07098858?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2025-11-03. Estimated completion is 2032-09-30.
What conditions does trial NCT07098858 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT07098858?
The interventions under investigation include: The Wise System (DEVICE).
Who is sponsoring clinical trial NCT07098858?
This trial is sponsored by EBR Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07098858 being conducted?
This trial has 5 study locations across Arkansas, Florida, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07098858's enrollment target sits among peer trials
320 134th of 397 higher than 261 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI